Celltrion Inc

🇧🇪Belgium
Ownership
-
Established
1999-01-01
Employees
-
Market Cap
$31.9B
Website
http://www.celltrion.com/
Clinical Trials
Related News

An Observational Study to Evaluate Safety and Efficacy of Remsimaâ„¢ in Patients With Ankylosing Spondylitis

Terminated
Conditions
Ankylosing Spondylitis
First Posted Date
2015-09-23
Last Posted Date
2024-12-09
Lead Sponsor
Celltrion
Target Recruit Count
329
Registration Number
NCT02557308
Locations
🇰🇷

TaeHwan Kim, Seoul, Korea, Republic of

To Evaluate the Safety and Efficacy of Remsimaâ„¢ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

First Posted Date
2014-12-25
Last Posted Date
2022-02-21
Lead Sponsor
Celltrion
Target Recruit Count
470
Registration Number
NCT02326155

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Phase 3
Completed
Conditions
Follicular Lymphoma
Interventions
Biological: CT-P10
Biological: Rituxan
First Posted Date
2014-10-09
Last Posted Date
2021-04-08
Lead Sponsor
Celltrion
Target Recruit Count
258
Registration Number
NCT02260804
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

First Posted Date
2014-06-13
Last Posted Date
2020-01-29
Lead Sponsor
Celltrion
Target Recruit Count
140
Registration Number
NCT02162771

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Phase 3
Completed
Conditions
HER2-positive Carcinoma of Breast
Interventions
Drug: Trastuzumab
First Posted Date
2014-06-13
Last Posted Date
2022-08-03
Lead Sponsor
Celltrion
Target Recruit Count
562
Registration Number
NCT02162667

PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis

First Posted Date
2014-05-29
Last Posted Date
2021-12-16
Lead Sponsor
Celltrion
Target Recruit Count
384
Registration Number
NCT02149121

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Biological: CT-P13
Biological: Remicade
First Posted Date
2014-03-26
Last Posted Date
2018-05-09
Lead Sponsor
Celltrion
Target Recruit Count
220
Registration Number
NCT02096861
Locations
🇺🇸

Nashville Medical Research Institute, Nashville, Tennessee, United States

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Phase 2
Completed
Conditions
Influenza A
Interventions
Drug: CT-P27
Drug: Placebo
First Posted Date
2014-02-26
Last Posted Date
2020-04-08
Lead Sponsor
Celltrion
Target Recruit Count
81
Registration Number
NCT02071914
Locations
🇬🇧

Retroscreen Virology Ltd., London, United Kingdom

Long-Term Efficacy and Safety of CT-P10 in Patients With RA

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Rituximab, MTX, folic acid
First Posted Date
2013-06-10
Last Posted Date
2015-11-26
Lead Sponsor
Celltrion
Target Recruit Count
87
Registration Number
NCT01873443
Locations
🇰🇷

Inha University College of Medicine Hospital, Incheon, Korea, Republic of

An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1

Phase 1
Completed
Conditions
Ankylosing Spondylitis
Interventions
Biological: Infliximab
First Posted Date
2012-04-05
Last Posted Date
2013-07-31
Lead Sponsor
Celltrion
Target Recruit Count
174
Registration Number
NCT01571206
Locations
🇰🇷

Inha University Hospital, Incheon, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy